Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806675 · ClinicalTrials.gov registry record · Phase 1
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
A Phase 1 study of Male Breast Cancer and Adult Glioblastoma, sponsored by Sanjiv Sam Gambhir.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01806675: Completed Phase 1 study of Male Breast Cancer and Adult Glioblastoma, sponsored by Sanjiv Sam Gambhir.
NCT01806675 is a Phase 1 study of Male Breast Cancer and Adult Glioblastoma that has completed, run by Sanjiv Sam Gambhir. The registered enrollment target is 25 participants, below the 35-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01806675, a Phase 1 study of Male Breast Cancer and Adult Glioblastoma, has completed, sponsored by Sanjiv Sam Gambhir.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.
Primary Outcome
Maximum standard uptake values (SUVmax) were assessed on the basis of position emission tomography (PET) scans using radiotracers 18F-FPPRGD2 and 18F-FDG at baseline and at regular medical care follow-up (6 to 12 weeks after initiation of treatment). The outcome is assessed as the difference in the maximum standard uptake values (SUVmax) values from baseline to follow-up for the 2 radiotracers, and will be reported for each disease type as the median with standard deviation.
Conditions Studied
Interventions
- DRUG 18F-fludeoxyglucose (18F-FDG)
- DRUG 18F-FPPRGD2
Study Locations (1)
California
- Stanford University, School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-03-04 |
| Est. Completion | 2019-04 |
| Phase | Phase 1 |
What the finished NCT01806675 record still lists
NCT01806675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 35-participant average among 14 other Male Breast Cancer trials with a reported enrollment target (29% lower).
The record links to 10 conditions, with Male Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F-fludeoxyglucose (18F-FDG) is the first listed.
NCT01806675 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01806675 about?
NCT01806675 is a clinical study titled "18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy". The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiv...
What is the current status of trial NCT01806675?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-03-04. Estimated completion is 2019-04.
What conditions does trial NCT01806675 study?
This clinical trial studies the following conditions: Male Breast Cancer, Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Colon Cancer.
What interventions are being tested in trial NCT01806675?
The interventions under investigation include: 18F-fludeoxyglucose (18F-FDG) (DRUG), 18F-FPPRGD2 (DRUG).
Who is sponsoring clinical trial NCT01806675?
This trial is sponsored by Sanjiv Sam Gambhir, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01806675 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Male Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01806675's enrollment target sits among peer trials
25 9th of 14 higher than 6 of 14 other Male Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Male Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
-
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
-
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI